Market Overview

UPDATE: Morgan Stanley Upgrades Alkermes plc to Overweight on New Pipeline Opportunities

Related ALKS
Bank Of America Q3 Small & Mid-Cap Biotech Preview
Alkermes PLC Announces Completion Of Patient Enrollment In Phase 2 Study Of ALKS 3831, A Novel, Broad-Spectrum Oral Antipsychotic

Morgan Stanley upgraded Alkermes plc (NASDAQ: ALKS) from Equal-weight to Overweight and raised the price target from $21.00 to $26.00.

Morgan Stanley noted, "We anticipate improving investor perception as Alkermes transitions from being an outsourced drug delivery tech co. to an innovation engine with higher-value internal candidates. … We added a key new pipeline drug (3831 for schizophrenia) due to new disclosure Jan. 4, and we have greater conviction that Alkermes can develop new drugs to offset patent expirations in 2019 and beyond."

Alkermes plc closed at $21.61 on Wednesday.

Latest Ratings for ALKS

DateFirmActionFromTo
Apr 2014Mizuho SecuritiesUpgradesNeutralBuy
Apr 2014Credit SuisseInitiates Coverage onOutperform
Jan 2014Goldman SachsMaintainsNeutral

View More Analyst Ratings for ALKS
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (ALKS)

Around the Web, We're Loving...

Get Benzinga's Newsletters